Autoimmune Antibodies in Rheumatology

Autoantibodies are immunoglobulins directed against the body's own antigens. In rheumatology they are both signposts of broken self-tolerance and, in some diseases, direct contributors to tissue injury. Patterns of autoantibodies — rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis, antinuclear and anti-double-stranded-DNA antibodies in lupus — help define and classify the systemic autoimmune diseases.

Definition

Autoantibodies are antibodies produced by an individual's immune system that bind self-antigens; in rheumatology they include rheumatoid factor, anti-citrullinated protein antibodies (ACPA), antinuclear antibodies (ANA), and antigen-specific antibodies such as anti-double-stranded-DNA.

Scope

The topic covers the major autoantibody systems used in rheumatology, what they recognise, how they are thought to arise, and how they relate to disease processes. It treats autoantibodies as immunologic and classificatory markers, not as standalone diagnostic tests with prescriptive cut-offs.

Core questions

• What self-antigens do the major rheumatologic autoantibodies recognise?
• How do autoantibodies arise from a loss of B-cell tolerance?
• Which autoantibodies are markers versus direct mediators of tissue damage?
• How do autoantibody profiles map onto disease classification?

Key concepts

• Rheumatoid factor (anti-Fc IgM/IgG)
• Anti-citrullinated protein antibodies (ACPA)
• Antinuclear antibodies (ANA)
• Anti-double-stranded-DNA and anti-Sm antibodies
• Loss of B-cell self-tolerance
• Immune-complex formation
• Autoantibodies as classification markers

Mechanisms

Autoantibodies emerge when B-cell tolerance to self breaks down, often after T-cell help and somatic hypermutation drive affinity maturation against self-antigens. Some antibodies, such as rheumatoid factor, recognise the Fc portion of IgG; anti-citrullinated protein antibodies target proteins modified by citrullination, a post-translational change linked to inflammation and described in the pathogenesis of rheumatoid arthritis by McInnes & Schett (2011). In lupus, antibodies against nuclear antigens including double-stranded DNA can form immune complexes that deposit in tissue and trigger inflammation, as reviewed by Tsokos (2011) and Rahman & Isenberg (2008). Autoantibodies can therefore be both markers of disease and, when they form pathogenic immune complexes, direct contributors to injury.

Clinical relevance

Autoantibody patterns inform how rheumatic diseases are classified — for example, anti-citrullinated protein antibodies are part of the 2010 rheumatoid arthritis classification criteria (Aletaha et al., 2010) — and they often appear before clinical disease, illustrating the preclinical phase of autoimmunity. This entry explains what the antibodies mean immunologically; it is not a guide to ordering or interpreting tests for an individual patient.

Epidemiology

Autoantibody frequencies vary by disease and population: rheumatoid factor and anti-citrullinated protein antibodies are found in a majority of established rheumatoid arthritis, while antinuclear antibodies are nearly universal in lupus but also occur at low titre in healthy people, as noted in the cited reviews. Exact prevalences depend on assay and threshold.

Evidence & guidelines

The 2010 ACR/EULAR rheumatoid arthritis classification criteria (Aletaha et al., 2010) formally incorporate serologic autoantibody status, reflecting the role of autoantibodies in defining disease for research and classification purposes.

History

The rheumatoid factor was described in the 1940s and the LE cell and antinuclear antibody phenomena soon after, reframing rheumatoid arthritis and lupus as autoimmune diseases. The recognition in the late twentieth and early twenty-first centuries that antibodies to citrullinated proteins are highly specific for rheumatoid arthritis refined both classification and mechanistic understanding, culminating in their inclusion in the 2010 classification criteria.

Debates

Are autoantibodies cause or consequence of disease?

For some specificities, such as anti-double-stranded-DNA in lupus nephritis, antibodies appear directly pathogenic through immune-complex deposition, while others may be markers of an underlying immune disturbance; disentangling marker from mediator remains an active question.

Key figures

• George Tsokos
• Iain McInnes
• Georg Schett
• David Isenberg

Seminal works

• mcinnes-schett-2011
• tsokos-2011
• aletaha-2010

Frequently asked questions

Does a positive antinuclear antibody test mean a person has lupus?

No. Antinuclear antibodies are sensitive but not specific; they occur in many autoimmune conditions and at low titre in healthy people, so they are interpreted only in the context of the whole clinical picture.

Why are anti-citrullinated protein antibodies important in rheumatoid arthritis?

They are highly specific for rheumatoid arthritis, can appear years before symptoms, and are incorporated into the disease's classification criteria, making them valuable markers of the underlying autoimmune process.